News

Barclays analyst Glen Santangelo raised the stock to Overweight from Underweight and lifted his target to $8 from $4.

The biotech company’s stock rises after Barclays gives it a double upgrade, citing confidence in upcoming FDA approvals.

Management is betting on a bigger year than ever, but investors seem to be waiting for a catch.

American States Water has quietly been increasing its dividend for over 70 years.

High-yield ETFs built purely on yield rankings carry a hidden flaw that only shows up when it's too late, and one fund uses a decade-long dividend track record as a filter before yield ever enters the picture.

Johnson & Johnson (JNJ) has declared a third quarter 2026 cash dividend of $1.34 per share, providing income focused investors with fresh information on the stock’s current payout profile and upcoming key dates. See our latest analysis for Johnson & Johnson. The latest dividend announcement comes shortly after Johnson & Johnson reported second quarter 2026 results, raised full year sales guidance to US$100.8b to US$101.4b, and secured FDA approval for its dual energy THERMOCOOL SMARTTOUCH SF...

The dividend looks secure. The share price is the harder call.

Johnson & Johnson’s model fair value sits at US$252.87 per share, with analysts keeping price targets anchored to that unchanged estimate. Recent research links those steady targets to a mix of optimism around Icotyde, Inlexzo and the broader drug pipeline, balanced against policy questions and partnership headwinds that could influence how investors think about execution risk. As you read on, you will see how these moving pieces shape the evolving Johnson & Johnson story and what to watch...

Management raised the bar two months ago, but the stock just shrugged. Here’s why the market is waiting for proof, not promises.

AMD, Under Armour downgraded: Wall Street's top analyst calls